Álvarez Aldean, Javier
Rivero Calle, Irene
Rodríguez Fernández, Rosa
Aceituno Mata, Susana
Bellmunt, Alba
Prades, Miriam
Law, Amy W.
López-Ibáñez de Aldecoa, Alejandra
Méndez, Cristina
García Somoza, María L.
Soto, Javier
Lozano, Virginia
Article History
Received: 7 February 2024
Accepted: 8 April 2024
First Online: 11 May 2024
Declarations
:
: This work was sponsored by Pfizer, S.L.U., Spain. Susana Aceituno Mata, Alba Bellmunt and Miriam Prades are employees of Outcomes’10, which received funding from Pfizer for the development of the study and this manuscript. Amy W. Law, Alejandra López-Ibáñez de Aldecoa, Cristina Méndez, María L. García Somoza, and Virginia Lozano are employees of Pfizer and may hold Pfizer stock. Javier Soto is a former employee of Pfizer and may hold Pfizer stock. Javier Álvarez Aldeán has collaborated in teaching activities funded by AstraZeneca, GlaxoSmithKline, MSD, Pfizer, Sanofi and Seqirus; has participated as an investigator in clinical trials for GlaxoSmithKline and Sanofi; and has participated as a consultant in Advisory Boards for AstraZeneca, GlaxoSmithKline, MSD, Pfizer and Sanofi. Irene Rivero Calle has received speaking fees from MSD, GSK, Sanofi and Pfizer; scholarships/research grants from Sanofi Pasteur, MSD, Novartis and Pfizer; consulting fees for Pfizer, MSD and Sanofi; has participated as a subinvestigator in clinical trials of vaccines from Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK with the funds paid to her institution; and belongs to the Board of Directors of the CAV-AEP. Rosa Rodríguez-Fernández has received fees for lectures from AbbVie, Pfizer, Merck, Astra-Zeneca and Sanofi and fees for participation in Advisory Boards from AbbVie, Sanofi, and Pfizer.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.